clinical trial · NCT05897424
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Alpha 1-Antitrypsin DeficiencyEmphysemaSAR447537
brief summary
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
started
Jun 20, 2024
primary completion
Jun 30, 2028
completion
Sep 30, 2028
last updated
Apr 13, 2026
detailed description
This is a Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema.
official title
A Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol